{"abstract": "Pfizer\u2019s latest offer for its rival seems cheap to shareholders who view AstraZeneca\u2019s turnaround as well advanced, Neil Unmack writes in Reuters Breakingviews.", "web_url": "https://dealbook.nytimes.com/2014/05/02/pfizer-has-yet-to-make-a-compelling-bid-to-astrazenecas-shareholders/", "snippet": "Pfizer\u2019s latest offer for its rival seems cheap to shareholders who view AstraZeneca\u2019s turnaround as well advanced, Neil Unmack writes in Reuters Breakingviews.", "lead_paragraph": "Pfizer\u2019s courtship of AstraZeneca looks like a hate-hate relationship. In January, the British pharmaceutical firm AstraZeneca viewed its larger rival\u2019s takeover proposal of 46.61 pounds a share as too low on cash, too risky, and too cheap to even talk about. Pfizer\u2019s latest proposal, an effort to get AstraZeneca to begin friendly talks, hasn\u2019t moved the needle much.", "source": "The New York Times", "multimedia": [{"rank": 0, "subtype": "xlarge", "caption": null, "credit": null, "type": "image", "url": "images/2014/05/03/business/dbpix-ian-read/dbpix-ian-read-articleLarge.jpg", "height": 444, "width": 600, "subType": "xlarge", "crop_name": "articleLarge", "legacy": {"xlarge": "images/2014/05/03/business/dbpix-ian-read/dbpix-ian-read-articleLarge.jpg", "xlargewidth": 600, "xlargeheight": 444}}, {"rank": 0, "subtype": "jumbo", "caption": null, "credit": null, "type": "image", "url": "images/2014/05/03/business/dbpix-ian-read/dbpix-ian-read-jumbo.jpg", "height": 758, "width": 1024, "subType": "jumbo", "crop_name": "jumbo", "legacy": {}}, {"rank": 0, "subtype": "superJumbo", "caption": null, "credit": null, "type": "image", "url": "images/2014/05/03/business/dbpix-ian-read/dbpix-ian-read-superJumbo.jpg", "height": 1516, "width": 2048, "subType": "superJumbo", "crop_name": "superJumbo", "legacy": {}}, {"rank": 0, "subtype": "thumbnail", "caption": null, "credit": null, "type": "image", "url": "images/2014/05/03/business/dbpix-ian-read/dbpix-ian-read-thumbStandard.jpg", "height": 75, "width": 75, "subType": "thumbnail", "crop_name": "thumbStandard", "legacy": {"thumbnail": "images/2014/05/03/business/dbpix-ian-read/dbpix-ian-read-thumbStandard.jpg", "thumbnailwidth": 75, "thumbnailheight": 75}}, {"rank": 0, "subtype": "thumbLarge", "caption": null, "credit": null, "type": "image", "url": "images/2014/05/03/business/dbpix-ian-read/dbpix-ian-read-thumbLarge.jpg", "height": 150, "width": 150, "subType": "thumbLarge", "crop_name": "thumbLarge", "legacy": {}}], "headline": {"main": "Pfizer Has Yet to Make a Compelling Bid to AstraZeneca\u2019s Shareholders", "kicker": "DealBook", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 1, "major": "N"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": 2, "major": "N"}, {"name": "organizations", "value": "AstraZeneca PLC", "rank": 3, "major": "N"}, {"name": "organizations", "value": "Pfizer Inc", "rank": 4, "major": "N"}, {"name": "glocations", "value": "Great Britain", "rank": 5, "major": "N"}], "pub_date": "2014-05-02T17:00:17+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Neil Unmack", "person": [{"firstname": "Neil", "middlename": null, "lastname": "Unmack", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/ec8aaf84-5b1a-5c5f-9984-1ea85ce62151", "word_count": 403, "uri": "nyt://article/ec8aaf84-5b1a-5c5f-9984-1ea85ce62151"}